In cisplatin-resistant TGCT PDX models, combined treatment with mTORC1/2 inhibitor and cisplatin led to the reduction of tumor growth53, validating that PI3K/Akt/mTORC pathway is one of the reasons for cisplatin resistance in TGCT. Here, AKT1 is linked to neoplasm.